Ardelyx (ARDX) Competitors $4.60 +0.12 (+2.68%) Closing price 04:00 PM EasternExtended Trading$4.58 -0.02 (-0.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. MRUS, ACLX, ACAD, SWTX, RARE, AAPG, PTGX, RNA, SRRK, and MLTXShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), Avidity Biosciences (RNA), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Merus Arcellx ACADIA Pharmaceuticals SpringWorks Therapeutics Ultragenyx Pharmaceutical Ascentage Pharma Group International Protagonist Therapeutics Avidity Biosciences Scholar Rock MoonLake Immunotherapeutics Ardelyx (NASDAQ:ARDX) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability. Which has more volatility & risk, ARDX or MRUS? Ardelyx has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Merus has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Do insiders and institutionals hold more shares of ARDX or MRUS? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 4.6% of Merus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ARDX or MRUS more profitable? Ardelyx has a net margin of -14.86% compared to Merus' net margin of -506.73%. Ardelyx's return on equity of -34.45% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-14.86% -34.45% -13.81% Merus -506.73%-35.99%-29.83% Do analysts recommend ARDX or MRUS? Ardelyx currently has a consensus price target of $10.89, suggesting a potential upside of 136.71%. Merus has a consensus price target of $84.64, suggesting a potential upside of 55.27%. Given Ardelyx's higher probable upside, equities research analysts plainly believe Ardelyx is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Does the media favor ARDX or MRUS? In the previous week, Ardelyx had 5 more articles in the media than Merus. MarketBeat recorded 8 mentions for Ardelyx and 3 mentions for Merus. Merus' average media sentiment score of 1.06 beat Ardelyx's score of 0.52 indicating that Merus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Merus 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, ARDX or MRUS? Ardelyx has higher revenue and earnings than Merus. Ardelyx is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.61M3.30-$39.14M-$0.22-20.91Merus$36.13M104.42-$215.33M-$4.08-13.36 SummaryArdelyx beats Merus on 9 of the 17 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$2.39B$5.51B$8.96BDividend YieldN/A1.80%5.25%4.02%P/E Ratio-20.919.2628.0520.15Price / Sales3.30771.14438.14127.85Price / CashN/A161.3437.0657.97Price / Book6.304.638.125.62Net Income-$39.14M$31.26M$3.16B$248.50M7 Day Performance9.79%6.81%4.40%5.54%1 Month Performance22.34%4.31%4.09%7.52%1 Year Performance-17.27%3.88%34.53%22.06% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.4255 of 5 stars$4.60+2.7%$10.89+136.7%-17.8%$1.07B$333.61M-20.9190Analyst RevisionMRUSMerus2.0831 of 5 stars$52.60-0.7%$84.64+60.9%-6.1%$3.64B$54.73M-12.8937News CoveragePositive NewsACLXArcellx2.3156 of 5 stars$65.85+0.8%$111.23+68.9%+19.3%$3.63B$107.94M-22.0280Positive NewsACADACADIA Pharmaceuticals4.6806 of 5 stars$21.57-2.5%$27.88+29.2%+28.8%$3.61B$996.28M15.74510SWTXSpringWorks Therapeutics1.6508 of 5 stars$46.99+0.0%$52.57+11.9%N/A$3.54B$191.59M-13.78230Positive NewsRAREUltragenyx Pharmaceutical4.0671 of 5 stars$36.36-0.4%$87.00+139.3%-5.0%$3.44B$590.69M-6.181,294News CoverageAAPGAscentage Pharma Group InternationalN/A$39.38-0.6%N/AN/A$3.43B$134.35M0.00600News CoveragePTGXProtagonist Therapeutics2.4513 of 5 stars$55.27-0.8%$66.10+19.6%+43.3%$3.43B$434.43M73.69120News CoveragePositive NewsRNAAvidity Biosciences2.4751 of 5 stars$28.40-2.2%$65.59+130.9%-24.3%$3.42B$10.90M-9.47190SRRKScholar Rock3.3049 of 5 stars$35.42-1.1%$42.67+20.5%+335.1%$3.36B$33.19M-14.00140MLTXMoonLake Immunotherapeutics1.9417 of 5 stars$47.20-0.7%$74.50+57.8%+7.4%$3.02BN/A-20.522News CoveragePositive News Related Companies and Tools Related Companies MRUS Competitors ACLX Competitors ACAD Competitors SWTX Competitors RARE Competitors AAPG Competitors PTGX Competitors RNA Competitors SRRK Competitors MLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDX Stock Alerts